Methyl 7-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylate → 6-(Hydroxymethyl)-7-methyl-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one

HRID 639027노트

반응식

HRID 639027 반응식
[CH3:1][C:2]1[C:11]([C:12](OC)=[O:13])=[N:10][C:9]2[NH:8][C:7](=[O:16])[CH2:6][S:5][C:4]=2[CH:3]=1>C1COCC1>[OH:13][CH2:12][C:11]1[C:2]([CH3:1])=[CH:3][C:4]2[S:5][CH2:6][C:7](=[O:16])[NH:8][C:9]=2[N:10]=1

참가 물질

3

반응물 1

HCID 21873746Methyl 7-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylate

생성물 1

HCID 218736326-(Hydroxymethyl)-7-methyl-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one

시약·촉매·용매 1

HCID 8028Tetrahydrofuran용매

반응 조건

온도
-10 °C

실험 절차

Methyl 7-methyl-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylate (54 mg, 0.195 mmol) was dissolved in THF (5 mL), cooled to −10° C. and treated with 1.0M LiH3BNMe2 (0.42 mL, 0.42 mmol). The reaction was maintained at −10° C. for 1 h and then quenched with 6N HCl. The reaction solution was diluted with EtOAc and water and the aqueous phase was extracted with EtOAc. The combined organic phases were dried (Na2SO4), filtered and concentrated. The crude product (30.3 mg) was used directly in the next step without further purification.

후처리

  1. additiontreated with 1.0M LiH3BNMe2 (0.42 mL, 0.42 mmol)
  2. temperatureThe reaction was maintained at −10° C. for 1 h
  3. customquenched with 6N HCl
  4. additionThe reaction solution was diluted with EtOAc and water
  5. extractionthe aqueous phase was extracted with EtOAc
  6. dry with materialThe combined organic phases were dried (Na2SO4)
  7. filtrationfiltered
  8. concentrationconcentrated
  9. customThe crude product (30.3 mg) was used directly in the next step without further purification

출처 및 근거

ORD 기록
ord-44167344f08a401b8a7525f4f3482b23
출처 데이터셋
uspto-grants-2010_04
특허 번호
US07691850B2

반응 노트

불러오는 중…